Skip to main content

Table 2 Correlation of ARID1a, BRG1 and BRM expression for the test corhort

From: Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma

  

ARID1a expression

 

BRG1 expression

 

BRM expression

 

Negative

Positive

p-value

  

Negative

Positive

p-value

  

Negative

Positive

p-value

Total

147*

 

14

9.5%

133

90.5%

 

149*

 

7

4.7%

142

95.3%

 

148*

 

17

11.5%

131

88.5%

 

Sex

 Female

13

8.8%

1

7.7%

12

92.3%

1.000

14

9.4%

0

0.0%

14

100.0%

1.000

14

9.5%

2

14.3%

12

85.7%

0.664

 Male

134

13.2%

13

9.7%

121

90.3%

135

90.6%

7

5.2%

128

94.8%

134

90.5%

15

11.2%

119

88.8%

Age group

 <65

63

46.3%

5

7.9%

58

92.1%

0.771

65

47.1%

2

3.1%

63

96.9%

0.447

65

47.4%

7

10.8%

58

89.2%

0.796

 >65

73

53.7%

8

11.0%

65

89.0%

73

52.9%

5

6.8%

68

93.2%

72

52.6%

9

12.5%

63

87.5%

pT stage

 1

21

14.4%

2

9.5%

19

90.5%

0.583

21

14.2%

1

4.8%

20

95.2%

0.107

21

14.3%

3

14.3%

18

85.7%

0.496

 2

13

8.9%

0

0.0%

13

100.0%

13

8.8%

0

0.0%

13

100.0%

13

8.8%

0

0.0%

13

100.0%

 3

109

74.7%

12

11.0%

97

89.0%

111

75.0%

5

4.5%

106

95.5%

110

74.8%

14

12.7%

96

87.3%

 4

3

2.1%

0

0.0%

3

100%

3

2.0%

1

0.0%

2

100%

3

2.0%

0

0.0%

3

100.0%

Lymph node metastasis

 pN0

54

37.0%

6

11.1%

48

88.9%

0.656

54

36.5%

3

5.6%

51

94.4%

0.832

54

36.7%

5

9.3%

49

90.7%

0.574

 pN 1

71

48.6%

5

7.0%

66

93.0%

71

48.0%

3

4.2%

68

95.8%

70

47.6%

8

11.4%

62

88.6%

 pN 2

10

6.8%

1

10.0%

9

90.0%

10

6.8%

0

0.0%

10

100.0%

10

6.8%

1

10.0%

9

90.0%

 pN 3

11

7.5%

2

18.2%

9

81.8%

13

8.8%

1

7.7%

12

92.3%

13

8.8%

3

23.1%

10

76.9%

Grading

 G1

0

0.0%

0

0.0%

0

0.0%

0.095

1

0.8%

0

0.0%

1

100.0%

0.901

1

0.8%

0

0.0%

1

100.0%

0.123

 G2

84

68.9%

5

6.0%

79

94.0%

84

67.7%

3

3.6%

81

96.4%

83

67.5%

8

9.6%

75

90.4%

 G3

38

31.1%

6

15.8%

32

84.2%

39

31.5%

2

5.1%

37

94.4%

39

31.7%

9

23.1%

30

76.9%

  1. *Total numbers of patients do not add due to missing clinical data in some cases